BioCryst Pharmaceuticals (BCRX) vs Trulieve Cannabis Subordinate Voting Shares (TRLV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Trulieve Cannabis Subordinate Voting Shares (TRLV) has outperformed BioCryst Pharmaceuticals (BCRX) over the past year, gaining 18.0% versus a gain of 13.9%. Over five years, BCRX leads with a -45.2% price change compared with -60.5% for TRLV. BioCryst Pharmaceuticals is the larger company by market cap ($2.12 billion vs $2.00 billion), about 1.1 times the size.
On valuation, BioCryst Pharmaceuticals trades at a lower forward P/E (8.8x vs 18.6x for Trulieve Cannabis Subordinate Voting Shares). BioCryst Pharmaceuticals converts more of its revenue into profit, with a net margin of 30.2% versus -10.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | TRLV |
|---|---|---|
| Share price | $8.29 | $10.37 |
| Market cap | $2.12B | $2.00B |
| 1-day change | -1.31% | -3.80% |
| YTD return | +6.28% | +19.33% |
| 1-year return | +13.87% | +17.97% |
| 5-year return | -45.21% | -60.45% |
| Forward P/E | 8.82 | 18.63 |
| EPS (TTM) | $-1.40 | $-2.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $874.84M | $1.18B |
| Revenue growth (YoY) | +94.10% | -0.45% |
| Net income (latest FY) | $263.86M | $-122.25M |
| Gross margin | 97.82% | 60.21% |
| Operating margin | 38.98% | 12.15% |
| Net margin | 30.16% | -10.35% |
| 52-week high | $11.22 | $13.28 |
| 52-week low | $6.00 | $4.62 |
| Distance from 52-week high | -26.11% | -21.91% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +150.06% | +75.31% |
| Average volume | 4.13M | 1.61M |
| Shares outstanding | 255.54M | 170.16M |
| Employees | 435 | 5,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioCryst Pharmaceuticals is more profitable, keeping 30.2 cents of every revenue dollar as net income versus -10.3 cents for Trulieve Cannabis Subordinate Voting Shares.
- BioCryst Pharmaceuticals grew revenue faster in its latest fiscal year (+94.10% vs -0.45%).
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Trulieve Cannabis Subordinate Voting Shares
TRLV stock →Trulieve Cannabis Corp. operates as a cannabis retailer in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 5,000 employees
BCRX vs TRLV FAQ
Which is bigger, BioCryst Pharmaceuticals or Trulieve Cannabis Subordinate Voting Shares?
BioCryst Pharmaceuticals (BCRX) is larger, with a market capitalization of $2.12B compared with $2.00B for Trulieve Cannabis Subordinate Voting Shares (TRLV).
Which stock has performed better over the past year, BCRX or TRLV?
TRLV returned +17.97% over the past 12 months, compared with +13.87% for BCRX (price return, excluding dividends). Past performance does not predict future results.
Are BioCryst Pharmaceuticals and Trulieve Cannabis Subordinate Voting Shares in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioCryst Pharmaceuticals and Medicinal Chemicals and Botanical Products for Trulieve Cannabis Subordinate Voting Shares.